Skip to main content
Premium Trial:

Request an Annual Quote

Canada Invests C$3M in Metabolomics Instruments

NEW YORK (GenomeWeb) – The Canadian Government today announced an investment of C$3 million (US$2.4 million) towards instruments to help establish the Metabolomics Technology Demonstration Centre, in partnership with Genome Alberta and the University of Alberta.

The instruments, a 700 MHz nuclear magnetic resonance machine and a quadrupole time-of-flight mass spectrometer, will assist companies in the metabolomics sector translate biomarker-based tests from the lab into the clinic. Companies will test, validate, and assemble prototypes using the University of Alberta Metabolomics Innovation Centre's biomarker panels, to create more accurate and less invasive medical tests.

"The Metabolomics Technology Demonstration Centre will provide Canadian researchers with cutting edge infrastructure and technical expertise to support translation of innovative biomarker discoveries into real life applications," David Wishart, professor of biological and computing sciences at the University of Alberta, said in a statement.

The National Institute of Nanotechnology, Alberta Innovates Health Solutions, Metabolomics Technologies, and Genome Canada are also contributors towards this project.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.